Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure: a prospective study.

OBJECTIVES We sought to prospectively compare the prognostic value of cardiac iodine-123 (I-123) metaiodobenzylguanidine (MIBG) imaging with that of heart rate variability (HRV) in patients with mild-to-moderate chronic heart failure (HF). BACKGROUND Cardiac I-123 MIBG imaging, which reflects cardiac adrenergic nerve activity, provides prognostic information on chronic HF patients. Reduced HRV, indicating derangement in cardiac autonomic control, was also reported to be associated with a poor prognosis in chronic HF patients. METHODS At study entry, I-123 MIBG imaging and 24-h Holter monitoring were performed in 65 chronic HF outpatients with a radionuclide left ventricular ejection fraction <40%. The cardiac MIBG heart to mediastinum ratio (H/M) and washout rate (WR) were obtained from MIBG imaging. The time and frequency domain parameters of HRV were calculated from 24-h Holter recordings. RESULTS At a mean follow-up of 34 +/- 19 months, WR (p < 0.0001), H/M on the delayed image (p = 0.01), and normalized very-low-frequency power (n-VLFP) (p = 0.047) showed a significant association with the cardiac events (sudden death in 3 and hospitalization for worsening chronic HF in 10 patients) on univariate analysis. Multivariate analysis revealed that WR was the only independent predictor of cardiac events, although the predictive accuracy for the combination of abnormal WR and n-VLFP significantly increased, compared with that for abnormal WR (82% vs. 66%, p < 0.05). CONCLUSIONS Cardiac MIBG WR has a higher prognostic value than HRV parameters in patients with chronic HF. The combination of abnormal WR and n-VLFP would be useful to identify chronic HF patients at a higher risk of cardiac events.

[1]  A. Malliani,et al.  Cardiovascular Neural Regulation Explored in the Frequency Domain , 1991, Circulation.

[2]  M. Miyagawa,et al.  Prognostic value of iodine-123-metaiodobenzylguanidine imaging and cardiac natriuretic peptide levels in patients with left ventricular dysfunction resulting from cardiomyopathy. , 2001, Japanese circulation journal.

[3]  N. Ohtomo,et al.  New Method of Time Series Analysis and Its Application to Wolf's Sunspot Number Data , 1994 .

[4]  M. Akers,et al.  Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. , 1988, Circulation.

[5]  R. Prescott,et al.  Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). , 1998, Circulation.

[6]  M. Packer The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. , 1992, Journal of the American College of Cardiology.

[7]  N. Clinthorne,et al.  Myocardial imaging with a radioiodinated norepinephrine storage analog. , 1981, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  P. Ponikowski,et al.  Detection and significance of a discrete very low frequency rhythm in RR interval variability in chronic congestive heart failure. , 1996, The American journal of cardiology.

[9]  G D Pinna,et al.  Abnormal awake respiratory patterns are common in chronic heart failure and may prevent evaluation of autonomic tone by measures of heart rate variability. , 1997, Circulation.

[10]  M. Hori,et al.  Prognostic significance of cardiac 123I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study , 2001, Heart.

[11]  P. Ponikowski,et al.  Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. , 1997, The American journal of cardiology.

[12]  D. Bonaduce,et al.  Independent and incremental prognostic value of heart rate variability in patients with chronic heart failure. , 1999, American heart journal.

[13]  F Boomsma,et al.  Prognostic value of heart rate variability during long-term follow-up in patients with mild to moderate heart failure. The Dutch Ibopamine Multicenter Trial Study Group. , 1996, Journal of the American College of Cardiology.

[14]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[15]  H. Figulla,et al.  Cardiac sympathetic activity as measured by myocardial 123-I-metaiodobenzylguanidine uptake and heart rate variability in idiopathic dilated cardiomyopathy. , 1999, The American journal of cardiology.

[16]  J. Fleiss,et al.  Correlations among time and frequency domain measures of heart period variability two weeks after acute myocardial infarction. , 1992, The American journal of cardiology.

[17]  A. Malliani,et al.  Heart rate variability. Standards of measurement, physiological interpretation, and clinical use , 1996 .

[18]  G. Breithardt,et al.  Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. , 1996 .

[19]  M. Hamon,et al.  Improvement of cardiac neuronal function after carvedilol treatment in dilated cardiomyopathy: a 123I-MIBG scintigraphic study. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  P. Merlet,et al.  Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  J. Floras Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure. , 1993, Journal of the American College of Cardiology.

[22]  A. DeMaria,et al.  Recommendations Regarding Quantitation in M-Mode Echocardiography: Results of a Survey of Echocardiographic Measurements , 1978, Circulation.

[23]  D. V. van Veldhuisen,et al.  Comparison between iodine 123 metaiodobenzylguanidine scintigraphy and heart rate variability for the assessment of cardiac sympathetic activity in mild to moderate heart failure. , 1997, American heart journal.

[24]  L. Fauchier,et al.  Prognostic value of heart rate variability for sudden death and major arrhythmic events in patients with idiopathic dilated cardiomyopathy. , 1999, Journal of the American College of Cardiology.

[25]  R. Spielmann,et al.  Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. , 1988, Journal of the American College of Cardiology.

[26]  S. Nakatani,et al.  Improvement in left ventricular function in response to carvedilol is accompanied by attenuation of neurohumoral activation in patients with dilated cardiomyopathy. , 2000, Journal of cardiac failure.

[27]  P. Merlet,et al.  Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. , 1999, Journal of the American College of Cardiology.

[28]  P. Korner,et al.  Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. , 1986, Circulation.

[29]  W. Mitsuoka,et al.  Iodine-123 metaiodobenzylguanidine images reflect intense myocardial adrenergic nervous activity in congestive heart failure independent of underlying cause. , 1995, Journal of the American College of Cardiology.

[30]  V. Dequattro,et al.  Liquid-chromatographic measurement of catecholamines and metabolites in plasma and urine. , 1987, Clinical chemistry.

[31]  G. Parati,et al.  Spectral analysis of blood pressure and heart rate variability in evaluating cardiovascular regulation. A critical appraisal. , 1995, Hypertension.